The report of the trial of the first phase of the first local vaccine in India against the Corona virus, Covaxin, showed an enhanced immune response without any serious side effects in the participants, according to the Lancet scientific journal, this comes in light of India’s continued largest vaccine campaign in the world, with the continuing global concerns about Side effects of vaccines, according to the Health Site report.
Kovaxin granted emergency permission from the Indian government
The Indian government granted permission to use covaxine in emergency situations in setting up a clinical trial, the vaccine was developed by Bharat Biotechnology in cooperation with the Indian Council of Medical Research (ICMR(And the National Institute of Virology)VIN), Bona.
Cofaxine–
The authors of the study funded by Bharat Biotechnology noted the covaxine vaccine, codenamed BBV152 , Was well tolerated in all dose groups with no serious adverse events associated with the vaccine.
The side effects are mild and moderate
According to the authors, all adverse events were mild and moderate, and were more frequent after the first dose, adding that one adverse event was reported but unrelated to the vaccine. A randomized phase 1 trial was performed to assess safety and immunity. BBV152 In 11 hospitals across India.
Cofaxine–
Adults between the ages of 18 and 55 whom the investigator considered to be in good health were eligible. Between the 13th and 30th of July of last year, 827 participants were examined, 375 of them were enrolled. Among the registered participants, 100 were assigned to each of them randomly to the three vaccine groups, and 75 were randomly assigned to the control group.
Cofaxine–
It is reported that Cofaxine is an inactivated vaccine that was developed by chemical treatment of samples of the new Corona virus to make them unable to reproduce, this process leaves the viral proteins, including the spiky protein of the coronavirus that it uses to enter human cells, intact.
– .
